COSETTE
Big PharmaCOSETTE is a major pharmaceutical company focused on Cardiovascular, Neurology. Key products include SYMPAZAN.
FDA Novel Drug Designations
(2019)See 1 novel approval →
COSETTE's Key Drugs
COSETTE's core commercial portfolio centers on SYMPAZAN, VYLEESI (AUTOINJECTOR), spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
COSETTE's Recent FDA Approvals
New NDA/BLA approvals for COSETTE over the last two years — novel drugs only, excluding generics and label supplements.
COSETTE's Therapeutic Areas
COSETTE's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 13 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
COSETTE's Top Competitors
COSETTE's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
COSETTE Pipeline Snapshot
Active clinical trials for COSETTE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SYMPAZAN leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (2)
Company Info
- First Approval
- 1978-02-09
- Latest
- 2026-02-24
- Applications
- 26